Patent · US Expired

Uses of mammalian CTLA-8 and related reagents

US6063372A · kind A · utility

12Cited by

0References

15Claims

0Family size

Assignees

INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE) · FR
SCHERING CORPORATION · US
Schering-Plough Corporation · FR

Inventors

Jacques F. Banchereau · Montclair, US
Odile Djossou · Lyon, FR
Leopoldo Flores-Romo · Houston, US
Francois Fossiez · Craponne, FR
Pierre Golstein · Marseilles, FR
Mala Krishna · Los Altos, US
Serge Lebecque · Écully, FR
Richard Murray · Pasadena, US

Key dates

Filing date	Oct 24, 1996
Grant date	May 16, 2000
Priority date	—
Expiry date	Oct 24, 2016

Classification

Technology area (CPC A)Human Necessities
CPC primaryA61K38/204
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

Compositions and methods for using CTLA-8 to treat an abnormal physiological condition in an individual. The methods comprise administering a therapeutically effective amount of CTLA-8 alone, or in combination with other therapeutic reagents; or a CTLA-8 antagonist.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.